Abstract
Recognition of the challenge of chronic obstructive pulmonary disease (COPD) worldwide has accompanied significant advances in our understanding of it and its treatment.1,2 Smoking, the main cause of COPD, continues to grow as falling sales of cigarettes in the developed world are balanced by a bumper market in the developing world. Tobacco addiction, so difficult to combat even in highly developed health care systems, achieves a customer loyalty seen only in opiate users. The damage that smokers incur is reflected in rates of cancer and heart disease that accounted for a third of all deaths between the ages of 35 and 70 years in the US at the height of their smoking epidemic.3 In contrast with these mortality statistics, the place of COPD in the overall impact of smoking has been neglected until recently. COPD causes almost as many deaths as lung cancer in the UK, for example, but where death is caused by COPD, it is invariably the final episode in a story of relentlessly progressive disability. Belated realization of the health services cost of COPD which is the commonest cause of emergency admissions in the UK has contributed to its growing prominence.4 But COPD is even more important worldwide. It is the second leading and main smoking-related cause of death in China.5